ClinicalTrials.gg
Not yet recruitingNCT06813326IPICAVEUpdated Feb 6, 2025

Interest of Nurse Participation During Epicutaneous-cavity Catheter Placement in Neonatal Intensive Care

An interventional study of catheter insertion in Premature Birth, sponsored by University Hospital, Clermont-Ferrand. Not yet recruiting at 1 site in France. Open to participants aged Up to 3 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-06.

Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
Up to 3 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 205 studies in Premature Birth with a site in France — 40 open to participants now, 46 under way, 2 of them phase 3. Premature Birth · France.

Planned enrollment
53rd of 104
96 · median 98
Started
2025
with 10 others
No phase
80 of 205
17 open now
Primary completion
2027-02
later than 29 of 45 live
Registered
187th of 205
by date
Lead sponsor
7 of 205
University Hospital, Clermont-Ferrand

Among the 205 studies in Premature Birth with a site in France, this one is the 53rd largest by planned enrollment of the 104 interventional ones that give a count, is one of 11 that started in 2025, is one of 80 with no phase, reaches primary completion later than 29 of the 45 other live ones, and was the 187th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

40 of the 205 studies in Premature Birth with a site in France are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: Up to 3 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Premature Birth with a site in France, or all of them as a file.
02

Study summary

To meet the needs of newborns in neonatal intensive care and ensure long-term venous access, a percutaneous central venous catheter (KTEC) is inserted. According to the recommendations of the French Society of Hospital Hygiene, the placement of this device is the responsibility of a medical professional. It may require several attempts to ensure the success of the procedure.

The pain associated with the needle insertion is generally controlled, but with repeated attempts, the newborn may become agitated, cry, and be difficult to calm. The study by Courtois et al. showed that pain in infants under 45 weeks of gestational age increased with the number of attempts. Acute and repeated pain in newborns can lead to trauma and disturbances in psychological, cognitive, and motor development.

In the neonatal intensive care unit (NICU) at the University Hospital of Clermont-Ferrand, the procedure is performed by the physician alone (i.e., "two hands"), whereas in other NICUs in France, the procedure is systematically performed by a nurse/physician team (i.e., "four hands"). However, no comparative study has been conducted to date to assess the impact of this "four hands" approach on the number of needle attempts and the pain experienced by the newborn.

The investogator hypothesize that the training and participation of the nurse (pediatric nurse) during the placement of the KTEC, in collaboration with the physician, could reduce the number of needle attempts and the newborn's pain. Therefore, the investigator aim to conduct a randomized, monocentric pilot study in the neonatal intensive care unit at the University Hospital of Clermont-Ferrand.

Read the detailed description

In the neonatal intensive care unit (NICU) of the University Hospital of Clermont-Ferrand (63), the study will begin with the training of a group of nurse practitioners (I(P)DE) to perform KTEC insertions in pairs over a six-month period. After this training, if a KTEC insertion is required, the investigator will ask the parents or guardians of eligible newborns for their consent to participate in the IPICAVE study (pre-inclusion visit).

If they agree, inclusion/randomization will take place after the parents or legal guardians sign the informed consent form for study participation.

The inclusion period will last for 18 months, and the study participation for each newborn will begin with the first needle insertion during the procedure and end at the conclusion of the dressing change after successful KTEC insertion or upon the last needle insertion if the attempt fails. During the KTEC insertion, the responsible I(P)DE will complete a data collection form to assess the various study criteria.

03

Conditions studied

  • Premature Birth

Keywords

  • newborn
  • neonatal intensive care
  • percutaneous central venous catheter
  • nurse
  • pain
  • shots
04

Who can participate

Ages eligible
Up to 3 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newborns born between 25 and 42 weeks of amenorrhea requiring KTEC insertion
  • Newborn whose parents or guardians have been informed of the study and are capable of providing to participate in the research.
  • Informed consent obtained from parents or guardians
  • Parents of legal age (≥18 years)

Exclusion criteria

Exclusion Criteria:

  • Parents under guardianship or curatorship, deprived of liberty or under court protection
  • Parents who do not speak or understand French
  • Newborn born under X
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    4 hand

    At D1, on the first attempt, the KTEC will be inserted by an I(P)DE/physician pair served by the nurse in charge of the child (whatever their level of experience) using the standard method, with no limit to the number of injections. At D2, if KTEC insertion fails at D1, a second attempt will be made, respecting the newborn's randomization arm. This second attempt must be carried out by an I(P)DE/doctor pair, with the nurse having a minimum of three years' seniority in a neonatal intensive care unit, and whose expertise will ensure successful insertion, with the number of injections limited to five. At D3, in the event of a further failure at D2, a third and final attempt will be made by a senior doctor, with no limit on the number of injections (to encourage success), in line with current department practice. Translated with DeepL.com (free version)

    Procedure: catheter insertion

  • Active comparator
    2 hand

    At D1, on the first attempt, the KTEC will be inserted by the doctor alone (junior or senior, depending on availability), assisted by the nurse responsible for the child, using the standard method, with no limit on the number of injections. On D2, if KTEC insertion fails on D1, a second attempt will be made, respecting the newborn's randomization arm. This second attempt must be made by a senior doctor in the department, whose expertise will help ensure successful insertion, with the number of injections limited to five. At D3, in the event of a further failure at D2, a third and final attempt will be made by another senior doctor, with no limit on the number of injections (to encourage success), in line with the department's current practice. Translated with DeepL.com (free version)

    Procedure: catheter insertion

Interventions

  • Procedurecatheter insertion

    success of catheter insertion

06

What researchers measure

Primary outcomes

  1. Successfull of KTEC insertion

    Total number of injections until successful KTEC insertion.

    Time frame: within day 3

Secondary outcomes

  1. success rate of the procedure.

    Success or failure of KTEC insertion.

    Time frame: within day 3

Other outcomes

  1. pain evaluation

    Average and maximum pain during injections, measured by hetero-evaluation scales

    Time frame: within day 3

  2. number of insertion attempts in cases of previous failure

    Total number of previous unsuccessful placement attempts

    Time frame: within day 3

  3. procedure time

    procedure time in minutes

    Time frame: within day 3

  4. Study the factors associated with the total number of bites

    number of bites according to the occurrence or non-occurrence of state of consciousness (awake or sedated newborn)

    Time frame: within day 3

  5. Study factors associated with average and maximum pain in newborns

    average and maximum pain according to state of gestational age (in weeks of amenorrhea: ˂29 , 29 to 32, 33 to 36, 37 to 42, and \>42)

    Time frame: within day 3

  6. hemoglobin levels

    Percentage change in hemoglobin between two consecutive days (dependent variable) and number of injections performed between the two hemoglobin measurements (independent variable)

    Time frame: within day 3

  7. Study the factors associated with the total number of bites

    number of bites according to catheter type (Premicath, Epicutaneocave, Nutriline twinflow)

    Time frame: within day 3

  8. Study factors associated with average and maximum pain in newborns

    average and maximum pain according to insertion site (left/right upper limb, left/right lower limb, skull)

    Time frame: within day 3

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Feb 2027, 19 months later.

Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 19 months is below that.

Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2025
First posted
Feb 6, 2025
StartEst.
Jul 1, 2025
Primary completionEst.
Feb 4, 2027
CompletionEst.
Feb 4, 2027
Last update
Feb 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06813326
Responsible party
Sponsor
First posted
Feb 6, 2025
Start date
Jul 1, 2025 (estimated)
Primary completion
Feb 4, 2027 (estimated)
Completion
Feb 4, 2027 (estimated)
Last update
Feb 6, 2025

Study contacts

Lise Laclautre
Contact
promo_interne_drci@chu-clermontferrand.fr
334.73.754.963
Nathalie SATURNIN LENOBLE
principal investigator · University Hospital, Clermont-Ferrand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion